Literature DB >> 20596801

Growth and differentiation properties of mesenchymal stromal cell populations derived from whole human umbilical cord.

Ingrida Majore1, Pierre Moretti, Frank Stahl, Ralf Hass, Cornelia Kasper.   

Abstract

Up to 2.8 × 10(7) fibroblast-like cells displaying an abundant presence of mesenchymal stem cell (MSC) markers CD73, CD90, CD105 and a low level of HLA-I expression can be isolated from one whole human umbilical cord (UC) using a simple and highly reproducible explant culture approach. Cells derived from whole UC, similar to cells collected from separate compartments of UC, display a distinct chondrogenic and adipogenic potential. Therefore they are potential candidates for cartilage and adipose tissue engineering. Cell differentiation along the osteogenic pathway is, however, less efficient, even after the addition of 1.25-dihydroxyvitamin D3, a potent osteoinductive substance. Isolated cells are highly proliferative, tolerate cryopreservation with an average survival rate of about 75% and after thawing can be propagated further, at least over 20 population doublings before their proliferative activity begins to decline. More importantly, they synthesize numerous trophic factors including neurotrophins and factors which facilitate angiogenesis and hematopoiesis. In conclusion, cells isolated from whole UC satisfies all requirements essential for the generation of stem cell banks containing permanently available cell material for applications in the field of regenerative medicine. Nevertheless, further studies are needed to improve and adjust the methods which are already employed for adult MSC expansion and differentiation to specific properties and requirements of the primitive stem cells collected from UC. So, our data verify that the choice of individual parameters for cell propagation, such as duration of cell expansion and cell seeding density, has a substantial impact on the quality of UC-derived cell populations.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20596801     DOI: 10.1007/s12015-010-9165-y

Source DB:  PubMed          Journal:  Stem Cell Rev Rep        ISSN: 2629-3277            Impact factor:   5.739


  23 in total

1.  Mesenchymal stem cells in the Wharton's jelly of the human umbilical cord.

Authors:  Hwai-Shi Wang; Shih-Chieh Hung; Shu-Tine Peng; Chun-Chieh Huang; Hung-Mu Wei; Yi-Jhih Guo; Yu-Show Fu; Mei-Chun Lai; Chin-Chang Chen
Journal:  Stem Cells       Date:  2004       Impact factor: 6.277

2.  Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement.

Authors:  E M Horwitz; K Le Blanc; M Dominici; I Mueller; I Slaper-Cortenbach; F C Marini; R J Deans; D S Krause; A Keating
Journal:  Cytotherapy       Date:  2005       Impact factor: 5.414

3.  Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoiesis-supportive function and other potentials.

Authors:  Lu-Lu Lu; Yong-Jun Liu; Shao-Guang Yang; Qin-Jun Zhao; Xin Wang; Wei Gong; Zhi-Bo Han; Zhen-Shu Xu; Yong-Xin Lu; Delong Liu; Zhi-Zhe Chen; Zhong-Chao Han
Journal:  Haematologica       Date:  2006-07-25       Impact factor: 9.941

4.  Comparison of mesenchymal stem cells derived from arterial, venous, and Wharton's jelly explants of human umbilical cord.

Authors:  Ikuo Ishige; Tokiko Nagamura-Inoue; Masaki J Honda; Ratanakanit Harnprasopwat; Michiko Kido; Mitsuhiro Sugimoto; Hiromitsu Nakauchi; Arinobu Tojo
Journal:  Int J Hematol       Date:  2009-08-06       Impact factor: 2.490

5.  Spontaneous human adult stem cell transformation.

Authors:  Daniel Rubio; Javier Garcia-Castro; María C Martín; Ricardo de la Fuente; Juan C Cigudosa; Alison C Lloyd; Antonio Bernad
Journal:  Cancer Res       Date:  2005-04-15       Impact factor: 12.701

6.  Umbilical cord Wharton's Jelly: a new potential cell source of mesenchymal stromal cells for bone tissue engineering.

Authors:  Tianyong Hou; Jianzhong Xu; Xuehui Wu; Zhao Xie; Fei Luo; Zehua Zhang; Ling Zeng
Journal:  Tissue Eng Part A       Date:  2009-09       Impact factor: 3.845

7.  Characterization of the optimal culture conditions for clinical scale production of human mesenchymal stem cells.

Authors:  Panagiota A Sotiropoulou; Sonia A Perez; Maria Salagianni; Constantin N Baxevanis; Michael Papamichail
Journal:  Stem Cells       Date:  2005-08-18       Impact factor: 6.277

8.  Human umbilical cord-derived cells can often serve as feeder cells to maintain primate embryonic stem cells in a state capable of producing hematopoietic cells.

Authors:  Takashi Hiroyama; Kazuhiro Sudo; Naoko Aoki; Kenichi Miharada; Inaho Danjo; Tsuyoshi Fujioka; Toshiro Nagasawa; Yukio Nakamura
Journal:  Cell Biol Int       Date:  2007-08-19       Impact factor: 3.612

9.  Human mesenchymal stem cells isolated from the umbilical cord.

Authors:  Chun Qiao; Wenrong Xu; Wei Zhu; Jiabo Hu; Hui Qian; Qing Yin; Runqiu Jiang; Yongmin Yan; Fei Mao; Huan Yang; Xingzhong Wang; Yongchang Chen
Journal:  Cell Biol Int       Date:  2007-08-19       Impact factor: 3.612

10.  Influence of three-dimensional hyaluronic acid microenvironments on mesenchymal stem cell chondrogenesis.

Authors:  Cindy Chung; Jason A Burdick
Journal:  Tissue Eng Part A       Date:  2009-02       Impact factor: 3.845

View more
  60 in total

Review 1.  Wharton's jelly mesenchymal stem cells as candidates for beta cells regeneration: extending the differentiative and immunomodulatory benefits of adult mesenchymal stem cells for the treatment of type 1 diabetes.

Authors:  Rita Anzalone; Melania Lo Iacono; Tiziana Loria; Antonino Di Stefano; Pantaleo Giannuzzi; Felicia Farina; Giampiero La Rocca
Journal:  Stem Cell Rev Rep       Date:  2011-06       Impact factor: 5.739

Review 2.  Musculoskeletal tissue engineering with human umbilical cord mesenchymal stromal cells.

Authors:  Limin Wang; Lindsey Ott; Kiran Seshareddy; Mark L Weiss; Michael S Detamore
Journal:  Regen Med       Date:  2011-01       Impact factor: 3.806

3.  Recent Patents Pertaining to Immune Modulation and Musculoskeletal Regeneration with Wharton's Jelly Cells.

Authors:  Limin Wang; Mark L Weiss; Michael S Detamore
Journal:  Recent Pat Regen Med       Date:  2013

Review 4.  The role of mesenchymal stem cells in bone repair and regeneration.

Authors:  Pavel Sponer; Tomáš Kučera; Daniel Diaz-Garcia; Stanislav Filip
Journal:  Eur J Orthop Surg Traumatol       Date:  2013-10-08

Review 5.  Mesenchymal stromal cells in the antimicrobial host response of hematopoietic stem cell recipients with graft-versus-host disease--friends or foes?

Authors:  A Balan; G Lucchini; S Schmidt; A Schneider; L Tramsen; S Kuçi; R Meisel; P Bader; T Lehrnbecher
Journal:  Leukemia       Date:  2014-04-03       Impact factor: 11.528

6.  Therapeutic efficacy of umbilical cord-derived mesenchymal stem cells in patients with type 2 diabetes.

Authors:  Li-Xue Guan; Hui Guan; Hai-Bo Li; Cui-Ai Ren; Lin Liu; Jin-Jin Chu; Long-Jun Dai
Journal:  Exp Ther Med       Date:  2015-03-09       Impact factor: 2.447

7.  Enhancing ex vivo expansion of cord blood-derived unrestricted somatic stem cells for clinical applications.

Authors:  Z Demerdash; H El Baz; F Mahmoud; S Mohamed; K Maher; T Gaafar; S Shawky; M Hassan; D Abdelhady; T Taha
Journal:  Cell Prolif       Date:  2013-12       Impact factor: 6.831

Review 8.  Umbilical cord-derived mesenchymal stem cells: Their advantages and potential clinical utility.

Authors:  Tokiko Nagamura-Inoue; Haiping He
Journal:  World J Stem Cells       Date:  2014-04-26       Impact factor: 5.326

9.  Effects of hypoxic culture conditions on umbilical cord-derived human mesenchymal stem cells.

Authors:  Antonina Lavrentieva; Ingrida Majore; Cornelia Kasper; Ralf Hass
Journal:  Cell Commun Signal       Date:  2010-07-16       Impact factor: 5.712

10.  Effect of EGF and FGF on the expansion properties of human umbilical cord mesenchymal cells.

Authors:  Parvin Salehinejad; Noorjahan Banu Alitheen; Ali Mandegary; Seyed Noureddin Nematollahi-Mahani; Ehsan Janzamin
Journal:  In Vitro Cell Dev Biol Anim       Date:  2013-05-25       Impact factor: 2.416

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.